Expert Interview
A Second Opinion: Discussing Pfizer's Phase 3 EV-303 Study of PADCEV Plus KEYTRUDA in Cisplatin-Ineligible Muscle-Invasive Bladder Cancer Patients
Ticker(s): PFE, MRK, ALPMFInstitution: Karmanos Cancer Center | Wayne State
- Director of the Phase I program at the Barbara Ann Karmanos Cancer Institute, and the Chief of Solid Tumor Oncology at Wayne State
- Developed, conducted and reported clinical studies in the field of early therapeutics and with a focus on GU malignancies.; site PI of the UM-1 grant from the national cancer Institute’s Early Therapeutics Cancer Research Network and is co-PI of the Prostate Cancer Clinical Trial consortium grant from the Department of Defense.
- Has conducted clinical research in the management of kidney cancers and clinical trials with a variety of novel agents in early therapeutics and translational settings. Her research interests also include trying to evaluate novel pathways and biomarkers in renal cancers.
Describe your background and practice setting
Added By: max_adminHow many patients with bladder cancer do you currently manage?
Added By: max_adminCan you describe the standard of care for bladder cancer?
Added By: max_adminWhere would this combination therapy fit into your treatment algorithm for bladder cancer?
Added By: max_adminRate your excitement for this combination therapy on a scale of 1-10
Added By: max_adminAre You Interested In These Questions?
Slingshot Insights Explained
- Call Date
- Mar 25, 2026
- Call Time
- 04:00 PM EDT
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
